However, further studies are needed to clarify the role of the aspartate/L-arginine axis in obesity and body fat distribution, and in particular, to determine whether oral supplementation with either L-arginine or aspartate may reduce fat deposition in the Cyp17a1 KO mouse model. This evidence concerns the gene CYP17A1 and Obesity.